Navigation Links
Popular Herbal Supplement Hinders the Growth of Pancreatic Cancer Cells

A new study from the University of Pittsburgh Cancer Institute suggests that a commonly used herbal supplement, triphala, has cancer-fighting properties// that prevent or slow the growth of pancreatic cancer tumors implanted in mice. The study found that an extract of triphala, the dried and powdered fruits of three plants, caused pancreatic cancer cells to die through a process called apoptosis – the body’s normal method of disposing of damaged, unwanted or unneeded cells. This process often is faulty in cancer cells. Results of the study, abstract number LB-142, are being presented in a late-breaking session at the annual meeting of the American Association for Cancer Research, April 14-18, at the Los Angeles Convention Center.

Triphala, one of the most popular herbal preparations in the world, is used for the treatment of intestinal-related disorders. It is typically taken with water and thought to promote appetite and digestion and to increase the number of red blood cells.

"We discovered that triphala fed orally to mice with human pancreatic tumors was an extremely effective inhibitor of the cancer process, inducing apoptosis in cancer cells," said Sanjay K. Srivastava, Ph.D., lead investigator and assistant professor, department of pharmacology, University of Pittsburgh School of Medicine. "Triphala triggered the cancerous cells to die off and significantly reduced the size of the tumors without causing any toxic side effects."

Dr. Srivastava and colleagues fed mice grafted with human pancreatic tumors 1 to 2 milligrams of triphala for five days a week and then compared tumor size and levels of apoptotic proteins in the tumors to a control group of mice that received normal saline only. They found that the mice that received triphala had increased levels of proteins associated with apoptosis and significantly smaller tumor sizes when compared to the control group. Triphala-treated tumors were half the size of tumors in untre
'"/>




Page: 1 2

Related medicine news :

1. Uterine Fibroid Embolization Gaining Popularity
2. Study Warns About The Use Of Popular Asthma Drug To Stop Childrens Coughs
3. Popularity Of Homeopathy On The Increase
4. Popularity Among Peers Increases Susceptibility To Smoking Habit Among School Children
5. Valentine Day Becoming Popular In India
6. Bio-functional Garments Gaining Popularity
7. Warfarin the Not So Popular Drug for Stroke
8. Tooth Enamel Eaten Away By Popular Drinks
9. Chinese NGO To Popularize Sex Education For Youngsters
10. Concerns About Popular Anti-Ulcer Pill Used For Inducing Labor
11. FDA issues warnings on Three Popular Asthma drug labels
Post Your Comments:
(Date:12/2/2008)...Newswire/ -- diaDexus, Inc. today,announced that ...mat of the,PLAC Test for Lp-PLA2. This automated ... a wide range of clinical chemistry analyzers, was...tration (FDA) in December 2007. diaDexus also,ann...st to Europe. , The PLAC Test is the only b...
(Date:12/2/2008)...t a symposium today hosted by Johns,Hopkins Univ...archers presented,the latest research in brain pl...cience into technology to improve lives. Henry Mah...vidence that cognitive intervention developed by,...brain,s ability to,reorganize itself throughout l...
(Date:12/2/2008)...ewswire/ -- Are you unhappy with your smile but ar...ailable? , , The Pennsylvania Dental Associ...ptions exist to improve your smile. Your dentist c... determine a suitable option to help restore your ...tal options. , , , , Tooth whi...
(Date:12/2/2008)...ed for 3.5 percent of high school athletes, injuri... to examine rare injuries and conditions of U.S. h...uries, dental injuries, neck and cervical injuries...t in high morbidity, costly surgeries and treatmen... associated with the highest rate of rare injuries...
Breaking Medicine News(10 mins):Health News:diaDexus Receives CE Mark Certification for the PLAC(R) Test 2Health News:Posit Science Invited to Speak at Johns Hopkins University About Cutting Edge Cognitive Training Interventions 2Health News:Cosmetic Dentistry: A Beautiful Smile Is Not Far Away 2
...riggered by viral cold are common in preschoolers....since the frequency disappears by school age. //Th...r oral steroids at the first sign of an attack. Bu...ive is controversial. The research shows a course...
...be a major improvement for HIV patients in less-de...sess a patient's response to HIV medication.// HIV... This treatment is now becoming available in Afric...etermine the CD4 cell count are needed. A low CD4 ...
...to help acne patients. A new study highlights the ...is is important because this skin disease can lead...b and sometimes even suicide. Doctors from London ...ate facial acne. Thirty-one of the patients receiv...
...is year’s meeting of the American Society of Thera...ment //of external beam radiation may be what it t...ers that have spread to the bone. More than 160 ho... States and Canada were involved in a study of abo...
Other Medicine News:
(Date:12/2/2008)... Horizon Therapeutics, Inc., a,pr...unced that two pivotal,Phase 3 trials evaluating ...1,met all primary endpoints. HZT-501, a novel, p...ing ibuprofen and famotidine, demonstrated a,stat...f non-steroidal,anti-inflammatory drug (NSAID)-in...
(Date:12/1/2008)...ICAGO, Dec. 2 A study h... a new technique for imaging the breast, is not af...nal status, two factors that limit the effectivene...ncer. Results will be presented today at the annua...rica (RSNA). , , "The ability of PEM to de...
(Date:12/1/2008)...RNewswire/ -- S*BIO Pte Ltd today announced the in...a potent and orally-active JAK2 inhibitor, in lead... chronic idiopathic myelofibrosis (CIMF). , ,...nd tolerability of SB1518 in patients with CIMF an...se 1 part of the study will assess the safety prof...
(Date:12/1/2008)... the Prox1 gene is a two-way switch that, if turne...programmed so that they lose their identity and be...MEMPHIS, Tenn., Dec. 1 ...al have discovered that a certain differentiated c...t requires the constant expression of a gene calle...
Breaking Medicine Technology:Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 2Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 3Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 4New Mammography Technology Effective in Detecting Breast Cancer 2New Mammography Technology Effective in Detecting Breast Cancer 3New Mammography Technology Effective in Detecting Breast Cancer 4S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis 2S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis 3Reprogrammable Cell Type Depends on a Single Gene to Keep Its Identity 2Reprogrammable Cell Type Depends on a Single Gene to Keep Its Identity 3After Effects 3A Giving Back Is Good for You 19422 1After Effects 3A Giving Back Is Good for You 19422 2Stable Stroke Patients More Likely to Die From a Nonstroke Cardiovascular Event Than a Further Stroke 5419 1Stable Stroke Patients More Likely to Die From a Nonstroke Cardiovascular Event Than a Further Stroke 5419 2Stable Stroke Patients More Likely to Die From a Nonstroke Cardiovascular Event Than a Further Stroke 5419 3Stable Stroke Patients More Likely to Die From a Nonstroke Cardiovascular Event Than a Further Stroke 5419 4Stable Stroke Patients More Likely to Die From a Nonstroke Cardiovascular Event Than a Further Stroke 5419 5Targeted therapy plus chemotherapy may pack 1 2 punch against melanoma 19417 1Targeted therapy plus chemotherapy may pack 1 2 punch against melanoma 19417 2AUA 2008 3A Global warming may lead to increase in kidney stones disease 19414 1
...IDGE, Mass.--(BUSINESS WIRE)--Jul 2, 2007 - ViaCel.... Beer, President and,Chief Executive Officer of V...ivities and product pipeline at the C.E. Unterberg...on Tuesday, July,10, 2007 at 3:00 p.m. at the Mand...webcast of the presentation will be available on,t...
...ESTER, Mass., Jun 27, 2007 (PrimeNewswire via COMT...ion (Nasdaq:GNBT), the,leader in drug delivery for...e mouth, announced today that it will be making th...g of the European,Society of Pediatric Endocrinolo...rget="_blank" href=,"http://www.espe2007.org/">www...
Other Medicine Technology:Generex Biotechnology to Make Presentations At 46th Annual Meeting,of the European Society of Pediatric Endocrinology 2Generex Biotechnology to Make Presentations At 46th Annual Meeting,of the European Society of Pediatric Endocrinology 3
... integrated technology and service--mobile,outpati...heartbeat, ECG monitoring, analysis and response, ...y focused on helping physicians diagnose and treat...in diagnosing and treating arrhythmia. Delays can ...
...rmance temperature controlled shaker which accommo...eed and incubation time are fully programmable via...ed on the LCD in real time. Microprocessor-control... provide uniform incubation with less than 0.6 C v...
The iEMS Incubator/Shaker HT is designed for extended temperatures. Thus, the iEMS Incubator/Shaker HT is ideal for applications such as DNA hybridization and primer extension assays. iEMS Incubator/
The iEMS Incubator/Shaker is a high performance microplate incubator and orbital shaker. Its superior temperature control and efficient orbital shaking reduce incubation times. -
Medicine Products: